Clinical Trials Logo

Post-ERCP Pancreatitis clinical trials

View clinical trials related to Post-ERCP Pancreatitis.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03749590 Terminated - Clinical trials for Post-ERCP Pancreatitis

Magnesium Sulfate in the Prevention of Post-ERCP Pancreatitis.

MagPEP
Start date: August 27, 2012
Phase: Phase 3
Study type: Interventional

MagPEP is a multi-centre, randomized, phase III, double blind, placebo controlled, parallel group trial. It evaluates magnesium sulfate for the prevention of post-ERCP pancreatitis. Adult patients with a medical indication for ERCP are to be randomized (1:1 ratio) to receive either magnesium sulfate or placebo (NaCl 0,9%) 60 min before and 6 hours after ERCP.

NCT ID: NCT00820612 Terminated - Clinical trials for Post-ERCP Pancreatitis

Rectal Indomethacin in the Prevention of Post-endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis in High Risk Patients

Start date: January 2009
Phase: Phase 4
Study type: Interventional

Pancreatitis (inflammation of the pancreas) is the most common complication of endoscopic retrograde cholangiopancreatography (ERCP), a procedure for the diagnosis and treatment of disorders of the pancreas and bile duct. Preliminary data has shown that non-steroidal antiinflammatory drugs, when administered rectally, can reduce the risk of pancreatitis after ERCP. This study is intended to definitively determine whether rectally administered indomethacin (a non-steroidal antiinflammatory drug)is effective at preventing pancreatitis after ERCP.